ClinicalTrials.gg
TerminatedNCT02460016Updated Jul 2, 2018

A Study of AK0529 in Infants Hospitalized With RSV

A Phase 1 interventional study of AK0529 in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Terminated at 1 site in Australia. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2018-07-02.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
We switched this study design to another study per IEC's recommendations.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia — 1 open to participants now, 6 under way, 1 of them phase 3. Respiratory Syncytial Virus Infections · Australia.

Enrollment
42nd of 44
1 · median 250
Started
2015
with 4 others
Phase 1
16 of 44
none open now
Registered
13th of 44
by date
Lead sponsor
3 of 44
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, this one is the 42nd largest by enrollment, is one of 5 that started in 2015, is one of 16 in phase 1, and was the 13th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single dose of AK0529 in infants hospitalized with respiratory syncytial virus (RSV).

Read the detailed description

This is a open-label Phase 1b study to evaluate the safety, tolerability, pharmacodynamics and Pharmacokinetics of AK0529 in hospitalized RSV infected infants age from 1 to 24 months.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects of any race or ethnicity with an age adjusted for any prematurity of ≥1 month and ≤24 months.
  • Diagnosis of RSV infection by virological.
  • Subject must weigh >3 kg at screening.
  • Must have provided written for the subject to participate.
  • For patients aged \<12 months, and occipitofrontal head circumference (OFHC) within the normal range for age and gender.

Exclusion criteria

Exclusion Criteria:

  • The subject has taken, is currently taking or requires any restricted medications.
  • Subject is known to be -positive (or the mother, if the potential subject is a child aged \<6 months).
  • Participation in an drug or device study within 30 days prior to the date of screening.
  • Requires vasopressors or inotropic support at the time of enrollment.
  • Concurrent gastrointestinal conditions that could, in the opinion of the investigator, prejudice absorption of the Investigational Medicinal Product (e.g. protracted vomiting, malabsorption syndrome, a history of necrotising enterocolitis with consequent short gut syndrome).
  • Bronchopulmonary dysplasia or chronic lung disease requiring assisted ventilation at the time of enrollment.
  • Diminished ventilatory reserve at risk for hypercapnia (e.g. pulmonary hypoplasia, sequestration syndromes, cystadenomatoid malformation, a history of surgery for diaphragmatic hernia).
  • Left to right shunt meriting corrective therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    AK0529

    AK0529 pellets

    Drug: AK0529

Interventions

  • DrugAK0529

    AK0529 pellets for oral administration

    Also known as: AK0529 pellets

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    Time frame: Baseline through 7 days post administration

Secondary outcomes

  1. Pharmacokinetics parameters, including maximum and minimum of drug concentration

    Time frame: Baseline through 3 days post administration

  2. Pharmacokinetics parameters, including time to maximum concentration and half-time

    Time frame: Baseline through 3 days post administration

  3. Pharmacokinetics parameters, including area under concentration-time curves (AUC)

    Time frame: Baseline through 3 days post administration

07

Study locations

1 site
  • Women's & Children's Hospital
    Adelaide, South Australia, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Nov 2015, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
Jun 2, 2015
StartActual
Aug 28, 2015
Primary completionActual
Nov 3, 2015
CompletionActual
Nov 3, 2015
Last update
Jul 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02460016
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2015
Start date
Aug 28, 2015
Primary completion
Nov 3, 2015
Completion
Nov 3, 2015
Last update
Jul 2, 2018

Study contacts

Stephen Toovey, MD PhD
study director · Shanghai Ark Biopharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion